vs
Blaize Holdings, Inc.（BZAI）与X4 Pharmaceuticals, Inc（XFOR）财务数据对比。点击上方公司名可切换其他公司
X4 Pharmaceuticals, Inc的季度营收约是Blaize Holdings, Inc.的1.2倍（$28.8M vs $23.8M），X4 Pharmaceuticals, Inc净利率更高（1.0% vs -13.9%，领先14.8%）
Blaize Holdings Inc.是一家专注于边缘人工智能计算解决方案的科技企业，主打低能耗AI处理器、低延迟推理软件栈及端到端边缘AI开发工具，核心服务自动驾驶、工业自动化、智慧城市、边缘医疗监测等应用场景。
X4制药是一家临床阶段生物技术公司，专注于开发针对存在高度未满足医疗需求的罕见免疫疾病和肿瘤适应症的新型靶向疗法，主要运营市场覆盖美国与欧洲，核心管线包括WHIM综合征候选药物及多款免疫疾病、肿瘤领域的临床和临床前资产。
BZAI vs XFOR — 直观对比
营收规模更大
XFOR
是对方的1.2倍
$23.8M
净利率更高
XFOR
高出14.8%
-13.9%
损益表 — Q4 FY2025 vs Q1 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.8M | $28.8M |
| 净利润 | $-3.3M | $282.0K |
| 毛利率 | 10.8% | 83.6% |
| 营业利润率 | -89.8% | -32.8% |
| 净利率 | -13.9% | 1.0% |
| 营收同比 | 2377500.0% | — |
| 净利润同比 | 50.7% | 100.5% |
| 每股收益（稀释后） | $0.16 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BZAIXFOR
| Q4 25 | $23.8M | — | ||
| Q3 25 | $11.9M | — | ||
| Q1 25 | — | $28.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 |
净利润BZAIXFOR
| Q4 25 | $-3.3M | — | ||
| Q3 25 | $-26.3M | — | ||
| Q1 25 | — | $282.0K | ||
| Q1 24 | — | $-51.8M | ||
| Q3 23 | — | $-2.3M | ||
| Q2 23 | — | $-55.7M |
毛利率BZAIXFOR
| Q4 25 | 10.8% | — | ||
| Q3 25 | 15.0% | — | ||
| Q1 25 | — | 83.6% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
营业利润率BZAIXFOR
| Q4 25 | -89.8% | — | ||
| Q3 25 | -190.3% | — | ||
| Q1 25 | — | -32.8% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
净利率BZAIXFOR
| Q4 25 | -13.9% | — | ||
| Q3 25 | -221.3% | — | ||
| Q1 25 | — | 1.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
每股收益（稀释后）BZAIXFOR
| Q4 25 | $0.16 | — | ||
| Q3 25 | $-0.25 | — | ||
| Q1 25 | — | $0.04 | ||
| Q1 24 | — | $-7.77 | ||
| Q3 23 | — | $-0.01 | ||
| Q2 23 | — | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $45.8M | $40.3M |
| 总债务越低越好 | — | $75.0M |
| 股东权益账面价值 | $39.0M | $22.9M |
| 总资产 | $102.2M | $130.0M |
| 负债/权益比越低杠杆越低 | — | 3.27× |
8季度趋势，按日历期对齐
现金及短期投资BZAIXFOR
| Q4 25 | $45.8M | — | ||
| Q3 25 | $24.0M | — | ||
| Q1 25 | — | $40.3M | ||
| Q1 24 | — | $60.5M | ||
| Q3 23 | — | $131.6M | ||
| Q2 23 | — | $136.4M |
总债务BZAIXFOR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | $75.0M | ||
| Q1 24 | — | $55.0M | ||
| Q3 23 | — | $55.0M | ||
| Q2 23 | — | $32.5M |
股东权益BZAIXFOR
| Q4 25 | $39.0M | — | ||
| Q3 25 | $1.3M | — | ||
| Q1 25 | — | $22.9M | ||
| Q1 24 | — | $1.0M | ||
| Q3 23 | — | $67.6M | ||
| Q2 23 | — | $67.5M |
总资产BZAIXFOR
| Q4 25 | $102.2M | — | ||
| Q3 25 | $60.9M | — | ||
| Q1 25 | — | $130.0M | ||
| Q1 24 | — | $112.2M | ||
| Q3 23 | — | $173.3M | ||
| Q2 23 | — | $173.4M |
负债/权益比BZAIXFOR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | 3.27× | ||
| Q1 24 | — | 53.09× | ||
| Q3 23 | — | 0.81× | ||
| Q2 23 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.5M | $-12.4M |
| 自由现金流经营现金流 - 资本支出 | $-16.5M | — |
| 自由现金流率自由现金流/营收 | -69.6% | — |
| 资本支出强度资本支出/营收 | 0.3% | 0.0% |
| 现金转化率经营现金流/净利润 | — | -43.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BZAIXFOR
| Q4 25 | $-16.5M | — | ||
| Q3 25 | $-24.9M | — | ||
| Q1 25 | — | $-12.4M | ||
| Q1 24 | — | $-33.6M | ||
| Q3 23 | — | $-68.8M | ||
| Q2 23 | — | $-47.9M |
自由现金流BZAIXFOR
| Q4 25 | $-16.5M | — | ||
| Q3 25 | $-24.9M | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | $-33.7M | ||
| Q3 23 | — | $-68.8M | ||
| Q2 23 | — | $-47.9M |
自由现金流率BZAIXFOR
| Q4 25 | -69.6% | — | ||
| Q3 25 | -210.2% | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
资本支出强度BZAIXFOR
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q1 25 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
现金转化率BZAIXFOR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | -43.86× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
